Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Polycythemia Vera 4Leukemia, Myeloid, Acute 4Treatment-Refractory Solid Tumors 2Meningioma 2Squamous Cell Carcinoma of Head and Neck 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Head and Neck Neoplasms 1Bone Marrow Neoplasms 1Bites and Stings 1

Interventions

Rituximab 53Cyclophosphamide 50Lenalidomide 41fludarabine 24obinutuzumab 23Prednisone 19Bendamustine Hydrochloride 19Magnetic Resonance Spectroscopy 18Vincristine 17Doxorubicin 16fludarabine phosphate 15Specimen Handling 15zanubrutinib 13Biopsy 12tazemetostat 10ibrutinib 10Whole-Body Irradiation 10pembrolizumab 9Peripheral Blood Stem Cell Transplantation 9venetoclax 8Mycophenolic Acid 7Etoposide 7axicabtagene ciloleucel 6Radiotherapy 6CT-P10 6Therapeutics 5R-CHOP protocol 5tafasitamab 4polatuzumab vedotin 4acalabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Hydroxyurea × 1 year × Clear all
NCT05020652 2026-06-02

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
107 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡